Stock, pipeline and biotech catalyst intelligence
Market expectations
Street view at a glance
The average target implies 95.7% upsideTargets are estimates—not guarantees—and can change after company updates.Wall Street consensus
Strong BuyBased on 8 analyst opinionsPrice-target range
$10.94Company profile
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.